Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 41

1.

Cistromic Reprogramming of the Diurnal Glucocorticoid Hormone Response by High-Fat Diet.

Quagliarini F, Mir AA, Balazs K, Wierer M, Dyar KA, Jouffe C, Makris K, Hawe J, Heinig M, Filipp FV, Barish GD, Uhlenhaut NH.

Mol Cell. 2019 Nov 21;76(4):531-545.e5. doi: 10.1016/j.molcel.2019.10.007. Epub 2019 Nov 6.

PMID:
31706703
2.

Evaluation of integrin αvβ6 cystine knot PET tracers to detect cancer and idiopathic pulmonary fibrosis.

Kimura RH, Wang L, Shen B, Huo L, Tummers W, Filipp FV, Guo HH, Haywood T, Abou-Elkacem L, Baratto L, Habte F, Devulapally R, Witney TH, Cheng Y, Tikole S, Chakraborti S, Nix J, Bonagura CA, Hatami N, Mooney JJ, Desai T, Turner S, Gaster RS, Otte A, Visser BC, Poultsides GA, Norton J, Park W, Stolowitz M, Lau K, Yang E, Natarajan A, Ilovich O, Srinivas S, Srinivasan A, Paulmurugan R, Willmann J, Chin FT, Cheng Z, Iagaru A, Li F, Gambhir SS.

Nat Commun. 2019 Oct 14;10(1):4673. doi: 10.1038/s41467-019-11863-w.

3.

CD271 is a molecular switch with divergent roles in melanoma and melanocyte development.

Filipp FV, Li C, Boiko AD.

Sci Rep. 2019 May 22;9(1):7696. doi: 10.1038/s41598-019-42773-y.

4.

Concurrent Targeting of Glutaminolysis and Metabotropic Glutamate Receptor 1 (GRM1) Reduces Glutamate Bioavailability in GRM1+ Melanoma.

Shah R, Singh SJ, Eddy K, Filipp FV, Chen S.

Cancer Res. 2019 Apr 15;79(8):1799-1809. doi: 10.1158/0008-5472.CAN-18-1500. Epub 2019 Apr 15.

PMID:
30987979
5.

Down-regulation of FZD3 receptor suppresses growth and metastasis of human melanoma independently of canonical WNT signaling.

Li C, Nguyen V, Clark KN, Zahed T, Sharkas S, Filipp FV, Boiko AD.

Proc Natl Acad Sci U S A. 2019 Mar 5;116(10):4548-4557. doi: 10.1073/pnas.1813802116. Epub 2019 Feb 21.

6.

The triennial International Pigment Cell Conference (IPCC).

Box NF, Larue L, Manga P, Montoliu L, Spritz RA, Filipp FV.

J Transl Med. 2018 Oct 3;16(1):252. doi: 10.1186/s12967-018-1609-1.

7.

Frontiers in pigment cell and melanoma research.

Filipp FV, Birlea S, Bosenberg MW, Brash D, Cassidy PB, Chen S, D'Orazio JA, Fujita M, Goh BK, Herlyn M, Indra AK, Larue L, Leachman SA, Le Poole C, Liu-Smith F, Manga P, Montoliu L, Norris DA, Shellman Y, Smalley KSM, Spritz RA, Sturm RA, Swetter SM, Terzian T, Wakamatsu K, Weber JS, Box NF.

Pigment Cell Melanoma Res. 2018 Nov;31(6):728-735. doi: 10.1111/pcmr.12728. Epub 2018 Oct 3.

8.

Chemoprevention agents for melanoma: A path forward into phase 3 clinical trials.

Jeter JM, Bowles TL, Curiel-Lewandrowski C, Swetter SM, Filipp FV, Abdel-Malek ZA, Geskin LJ, Brewer JD, Arbiser JL, Gershenwald JE, Chu EY, Kirkwood JM, Box NF, Funchain P, Fisher DE, Kendra KL, Marghoob AA, Chen SC, Ming ME, Albertini MR, Vetto JT, Margolin KA, Pagoto SL, Hay JL, Grossman D, Ellis DL, Kashani-Sabet M, Mangold AR, Markovic SN, Nelson KC, Powers JG, Robinson JK, Sahni D, Sekulic A, Sondak VK, Wei ML, Zager JS, Dellavalle RP, Thompson JA, Weinstock MA, Leachman SA, Cassidy PB.

Cancer. 2019 Jan 1;125(1):18-44. doi: 10.1002/cncr.31719. Epub 2018 Oct 3. Review. Erratum in: Cancer. 2019 Aug 1;125(15):2706.

PMID:
30281145
9.

A network of epigenomic and transcriptional cooperation encompassing an epigenomic master regulator in cancer.

Wilson S, Filipp FV.

NPJ Syst Biol Appl. 2018 Jul 1;4:24. doi: 10.1038/s41540-018-0061-4. eCollection 2018.

10.

Systems biology analysis of mitogen activated protein kinase inhibitor resistance in malignant melanoma.

Zecena H, Tveit D, Wang Z, Farhat A, Panchal P, Liu J, Singh SJ, Sanghera A, Bainiwal A, Teo SY, Meyskens FL Jr, Liu-Smith F, Filipp FV.

BMC Syst Biol. 2018 Apr 4;12(1):33. doi: 10.1186/s12918-018-0554-1.

11.

Metabolic shift in density-dependent stem cell differentiation.

Singh SJ, Turner W, Glaser DE, McCloskey KE, Filipp FV.

Cell Commun Signal. 2017 Oct 20;15(1):44. doi: 10.1186/s12964-017-0173-2.

12.

Metabolic profiling of triple-negative breast cancer cells reveals metabolic vulnerabilities.

Lanning NJ, Castle JP, Singh SJ, Leon AN, Tovar EA, Sanghera A, MacKeigan JP, Filipp FV, Graveel CR.

Cancer Metab. 2017 Aug 22;5:6. doi: 10.1186/s40170-017-0168-x. eCollection 2017.

13.

Insulin induces a shift in lipid and primary carbon metabolites in a model of fasting-induced insulin resistance.

Olmstead KI, La Frano MR, Fahrmann J, Grapov D, Viscarra JA, Newman JW, Fiehn O, Crocker DE, Filipp FV, Ortiz RM.

Metabolomics. 2017 May;13(5). pii: 60. doi: 10.1007/s11306-017-1186-y. Epub 2017 Mar 27.

14.

The histone demethylase KDM3A regulates the transcriptional program of the androgen receptor in prostate cancer cells.

Wilson S, Fan L, Sahgal N, Qi J, Filipp FV.

Oncotarget. 2017 May 2;8(18):30328-30343. doi: 10.18632/oncotarget.15681.

15.

An epigenetic master regulator teams up to become an epioncogene.

Qi J, Filipp FV.

Oncotarget. 2017 May 2;8(18):29538-29539. doi: 10.18632/oncotarget.16484. No abstract available.

16.

Crosstalk between epigenetics and metabolism-Yin and Yang of histone demethylases and methyltransferases in cancer.

Filipp FV.

Brief Funct Genomics. 2017 Nov 1;16(6):320-325. doi: 10.1093/bfgp/elx001. Review.

17.

Precision medicine driven by cancer systems biology.

Filipp FV.

Cancer Metastasis Rev. 2017 Mar;36(1):91-108. doi: 10.1007/s10555-017-9662-4.

18.
19.

EZH2 as a mediator of treatment resistance in melanoma.

Tiffen JC, Gallagher SJ, Tseng HY, Filipp FV, Fazekas de St. Groth B, Hersey P.

Pigment Cell Melanoma Res. 2016 Sep;29(5):500-7. doi: 10.1111/pcmr.12481. Epub 2016 May 25. Review.

21.

Hypermutation of DPYD Deregulates Pyrimidine Metabolism and Promotes Malignant Progression.

Edwards L, Gupta R, Filipp FV.

Mol Cancer Res. 2016 Feb;14(2):196-206. doi: 10.1158/1541-7786.MCR-15-0403. Epub 2015 Nov 25.

22.

Targeting activating mutations of EZH2 leads to potent cell growth inhibition in human melanoma by derepression of tumor suppressor genes.

Tiffen JC, Gunatilake D, Gallagher SJ, Gowrishankar K, Heinemann A, Cullinane C, Dutton-Regester K, Pupo GM, Strbenac D, Yang JY, Madore J, Mann GJ, Hayward NK, McArthur GA, Filipp FV, Hersey P.

Oncotarget. 2015 Sep 29;6(29):27023-36. doi: 10.18632/oncotarget.4809.

23.

Pharmacogenomic and clinical data link non-pharmacokinetic metabolic dysregulation to drug side effect pathogenesis.

Zielinski DC, Filipp FV, Bordbar A, Jensen K, Smith JW, Herrgard MJ, Mo ML, Palsson BO.

Nat Commun. 2015 Jun 9;6:7101. doi: 10.1038/ncomms8101.

24.

Cancer systems biology of TCGA SKCM: efficient detection of genomic drivers in melanoma.

Guan J, Gupta R, Filipp FV.

Sci Rep. 2015 Jan 20;5:7857. doi: 10.1038/srep07857.

25.

A Gateway between Omics Data and Systems Biology.

Filipp FV.

J Metabolomics Syst Biol. 2013 Nov 1;1(1):1.

26.

Cancer metabolism meets systems biology: Pyruvate kinase isoform PKM2 is a metabolic master regulator.

Filipp FV.

J Carcinog. 2013 Jul 24;12:14. doi: 10.4103/1477-3163.115423. eCollection 2013.

27.

Reversing the rewiring of cancer.

Filipp FV.

Int Innov. 2013;2013(22):113. No abstract available.

28.

Glutamine-fueled mitochondrial metabolism is decoupled from glycolysis in melanoma.

Filipp FV, Ratnikov B, De Ingeniis J, Smith JW, Osterman AL, Scott DA.

Pigment Cell Melanoma Res. 2012 Nov;25(6):732-9. doi: 10.1111/pcmr.12000. Epub 2012 Oct 1. Review.

29.

Reverse TCA cycle flux through isocitrate dehydrogenases 1 and 2 is required for lipogenesis in hypoxic melanoma cells.

Filipp FV, Scott DA, Ronai ZA, Osterman AL, Smith JW.

Pigment Cell Melanoma Res. 2012 May;25(3):375-83. doi: 10.1111/j.1755-148X.2012.00989.x. Epub 2012 Mar 27.

30.

Unusual binding of ursodeoxycholic acid to ileal bile acid binding protein: role in activation of FXRα.

Fang C, Filipp FV, Smith JW.

J Lipid Res. 2012 Apr;53(4):664-73. doi: 10.1194/jlr.M021733. Epub 2012 Jan 5.

31.

Comparative metabolic flux profiling of melanoma cell lines: beyond the Warburg effect.

Scott DA, Richardson AD, Filipp FV, Knutzen CA, Chiang GG, Ronai ZA, Osterman AL, Smith JW.

J Biol Chem. 2011 Dec 9;286(49):42626-34. doi: 10.1074/jbc.M111.282046. Epub 2011 Oct 13.

32.

Binding and "pKa" modulation of a polycyclic substrate analogue in a type II polyketide acyl carrier protein.

Haushalter RW, Filipp FV, Ko KS, Yu R, Opella SJ, Burkart MD.

ACS Chem Biol. 2011 May 20;6(5):413-8. doi: 10.1021/cb200004k. Epub 2011 Feb 22.

33.

Labeling strategies for 13C-detected aligned-sample solid-state NMR of proteins.

Filipp FV, Sinha N, Jairam L, Bradley J, Opella SJ.

J Magn Reson. 2009 Dec;201(2):121-30. doi: 10.1016/j.jmr.2009.08.012. Epub 2009 Sep 2.

34.

Structural basis for competitive interactions of Pex14 with the import receptors Pex5 and Pex19.

Neufeld C, Filipp FV, Simon B, Neuhaus A, Schüller N, David C, Kooshapur H, Madl T, Erdmann R, Schliebs W, Wilmanns M, Sattler M.

EMBO J. 2009 Mar 18;28(6):745-54. doi: 10.1038/emboj.2009.7. Epub 2009 Feb 5.

35.

Tailoring 13C labeling for triple-resonance solid-state NMR experiments on aligned samples of proteins.

Sinha N, Filipp FV, Jairam L, Park SH, Bradley J, Opella SJ.

Magn Reson Chem. 2007 Dec;45 Suppl 1:S107-15.

36.

Probing lipid- and drug-binding domains with fluorescent dyes.

Black SL, Stanley WA, Filipp FV, Bhairo M, Verma A, Wichmann O, Sattler M, Wilmanns M, Schultz C.

Bioorg Med Chem. 2008 Feb 1;16(3):1162-73. Epub 2007 Nov 19.

37.

Conformational plasticity of the lipid transfer protein SCP2.

Filipp FV, Sattler M.

Biochemistry. 2007 Jul 10;46(27):7980-91. Epub 2007 Jun 13.

38.

Recognition of a functional peroxisome type 1 target by the dynamic import receptor pex5p.

Stanley WA, Filipp FV, Kursula P, Schüller N, Erdmann R, Schliebs W, Sattler M, Wilmanns M.

Mol Cell. 2006 Dec 8;24(5):653-663. doi: 10.1016/j.molcel.2006.10.024.

39.

Determinants of conformational dimerization of Mad2 and its inhibition by p31comet.

Mapelli M, Filipp FV, Rancati G, Massimiliano L, Nezi L, Stier G, Hagan RS, Confalonieri S, Piatti S, Sattler M, Musacchio A.

EMBO J. 2006 Mar 22;25(6):1273-84. Epub 2006 Mar 9.

40.
41.

Topography for independent binding of alpha-helical and PPII-helical ligands to a peroxisomal SH3 domain.

Douangamath A, Filipp FV, Klein AT, Barnett P, Zou P, Voorn-Brouwer T, Vega MC, Mayans OM, Sattler M, Distel B, Wilmanns M.

Mol Cell. 2002 Nov;10(5):1007-17.

Supplemental Content

Loading ...
Support Center